42 results on '"Bystry V"'
Search Results
2. STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma
- Author
-
Lobello, C, Tichy, B, Bystry, V, Radova, L, Filip, D, Mraz, M, Montes-Mojarro, I, Prokoph, N, Larose, H, Liang, H, Sharma, G, Mologni, L, Belada, D, Kamaradova, K, Fend, F, Gambacorti Passerini, C, Merkel, O, Turner, S, Janikova, A, Pospisilova, S, Lobello C., Tichy B., Bystry V., Radova L., Filip D., Mraz M., Montes-Mojarro I. -A., Prokoph N., Larose H., Liang H. -C., Sharma G. G., Mologni L., Belada D., Kamaradova K., Fend F., Gambacorti Passerini C., Merkel O., Turner S. D., Janikova A., Pospisilova S., Lobello, C, Tichy, B, Bystry, V, Radova, L, Filip, D, Mraz, M, Montes-Mojarro, I, Prokoph, N, Larose, H, Liang, H, Sharma, G, Mologni, L, Belada, D, Kamaradova, K, Fend, F, Gambacorti Passerini, C, Merkel, O, Turner, S, Janikova, A, Pospisilova, S, Lobello C., Tichy B., Bystry V., Radova L., Filip D., Mraz M., Montes-Mojarro I. -A., Prokoph N., Larose H., Liang H. -C., Sharma G. G., Mologni L., Belada D., Kamaradova K., Fend F., Gambacorti Passerini C., Merkel O., Turner S. D., Janikova A., and Pospisilova S.
- Published
- 2021
3. Memory B-cell like chronic lymphocytic leukaemia is associated with specific methylation profile of WNT5A promoter and undetectable expression of WNT5A gene
- Author
-
Poppova, L, Pavlova, S, Gonzalez, B, Kotaskova, J, Plevova, K, Dumbovic, G, Janovska, P, Bystry, V, Panovska, A, Bezdekova, L, Maslejova, S, Brychtova, Y, Doubek, M, Krzyzankova, M, Borsky, M, Mayer, J, Bryja, V, Alonso, S, and Pospisilova, S
- Subjects
m-CLL ,methylation ,WNT5A ,i-CLL ,chronic lymphocytic leukaemia - Abstract
Genome methylation profiles define naive-like (n-CLL), memory-like (m-CLL), and intermediate (i-CLL) subsets of chronic lymphocytic leukaemia (CLL). The profiles can be easily determined by the analysis of the five-CpG signature. m-CLL, i-CLL, and n-CLL with the good, intermediate, and poor prognoses, respectively, differ by the somatic hypermutation status of the immunoglobulin heavy chain variable gene (IGHV), a widely used prognostic predictor in CLL. We have previously shown that the expression of WNT5A, encoding a ROR1 ligand, distinguishes patients with the worse outcome within the prognostically favourable IGHV-mutated subgroup. To analyse the mechanisms controlling WNT5A expression, we investigated the methylation status of 54 CpG sites within the WNT5A promoter and its relation to the WNT5A gene expression. In a cohort of 59 CLL patients balanced for combinations of IGHV and WNT5A statuses, we identified three promoter CpG sites whose methylation level correlated with the WNT5A expression within the IGHV-mutated subgroup. Further, we complemented our data with the methylation status of the five-CpG signature. IGHV-mutated/WNT5A-negative and IGHV-mutated/WNT5A-positive cases overlapped with m-CLL and i-CLL methylation subgroups, respectively, while most IGHV-unmutated samples were assigned to n-CLL. Median methylation levels of all the three CpG sites in the WNT5A promoter were lowest in i-CLL. Finally, a detailed analysis of m-CLL and i-CLL showed that undetectable WNT5A expression predicts longer treatment-free survival with higher statistical significance than the classification according to the five-CpG signature. To conclude, a favourable m-CLL subgroup is associated with mutated IGHV and undetectable WNT5A expression due to its promoter methylation.
- Published
- 2022
4. Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS
- Author
-
Knecht, H, Reigl, T, Kotrova, M, Appelt, F, Stewart, P, Bystry, V, Krejci, A, Grioni, A, Pal, K, Stranska, K, Plevova, K, Rijntjes, J, Songia, S, Svaton, M, Fronkova, E, Bartram, J, Scheijen, B, Herrmann, D, Garcia-Sanz, R, Hancock, J, Moppett, J, van Dongen, J, Cazzaniga, G, Davi, F, Groenen, P, Hummel, M, Macintyre, E, Stamatopoulos, K, Trka, J, Langerak, A, Gonzalez, D, Pott, C, Bruggemann, M, Darzentas, N, Knecht H., Reigl T., Kotrova M., Appelt F., Stewart P., Bystry V., Krejci A., Grioni A., Pal K., Stranska K., Plevova K., Rijntjes J., Songia S., Svaton M., Fronkova E., Bartram J., Scheijen B., Herrmann D., Garcia-Sanz R., Hancock J., Moppett J., van Dongen J. J. M., Cazzaniga G., Davi F., Groenen P. J. T. A., Hummel M., Macintyre E. A., Stamatopoulos K., Trka J., Langerak A. W., Gonzalez D., Pott C., Bruggemann M., Darzentas N., Knecht, H, Reigl, T, Kotrova, M, Appelt, F, Stewart, P, Bystry, V, Krejci, A, Grioni, A, Pal, K, Stranska, K, Plevova, K, Rijntjes, J, Songia, S, Svaton, M, Fronkova, E, Bartram, J, Scheijen, B, Herrmann, D, Garcia-Sanz, R, Hancock, J, Moppett, J, van Dongen, J, Cazzaniga, G, Davi, F, Groenen, P, Hummel, M, Macintyre, E, Stamatopoulos, K, Trka, J, Langerak, A, Gonzalez, D, Pott, C, Bruggemann, M, Darzentas, N, Knecht H., Reigl T., Kotrova M., Appelt F., Stewart P., Bystry V., Krejci A., Grioni A., Pal K., Stranska K., Plevova K., Rijntjes J., Songia S., Svaton M., Fronkova E., Bartram J., Scheijen B., Herrmann D., Garcia-Sanz R., Hancock J., Moppett J., van Dongen J. J. M., Cazzaniga G., Davi F., Groenen P. J. T. A., Hummel M., Macintyre E. A., Stamatopoulos K., Trka J., Langerak A. W., Gonzalez D., Pott C., Bruggemann M., and Darzentas N.
- Abstract
Assessment of clonality, marker identification and measurement of minimal residual disease (MRD) of immunoglobulin (IG) and T cell receptor (TR) gene rearrangements in lymphoid neoplasms using next-generation sequencing (NGS) is currently under intensive development for use in clinical diagnostics. So far, however, there is a lack of suitable quality control (QC) options with regard to standardisation and quality metrics to ensure robust clinical application of such approaches. The EuroClonality-NGS Working Group has therefore established two types of QCs to accompany the NGS-based IG/TR assays. First, a central polytarget QC (cPT-QC) is used to monitor the primer performance of each of the EuroClonality multiplex NGS assays; second, a standardised human cell line-based DNA control is spiked into each patient DNA sample to work as a central in-tube QC and calibrator for MRD quantification (cIT-QC). Having integrated those two reference standards in the ARResT/Interrogate bioinformatic platform, EuroClonality-NGS provides a complete protocol for standardised IG/TR gene rearrangement analysis by NGS with high reproducibility, accuracy and precision for valid marker identification and quantification in diagnostics of lymphoid malignancies.
- Published
- 2019
5. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study
- Author
-
Bruggemann, M, Kotrova, M, Knecht, H, Bartram, J, Boudjogrha, M, Bystry, V, Fazio, G, Fronkova, E, Giraud, M, Grioni, A, Hancock, J, Herrmann, D, Jimenez, C, Krejci, A, Moppett, J, Reigl, T, Salson, M, Scheijen, B, Schwarz, M, Songia, S, Svaton, M, van Dongen, J, Villarese, P, Wakeman, S, Wright, G, Cazzaniga, G, Davi, F, Garcia-Sanz, R, Gonzalez, D, Groenen, P, Hummel, M, Macintyre, E, Stamatopoulos, K, Pott, C, Trka, J, Darzentas, N, Langerak, A, Bruggemann M., Kotrova M., Knecht H., Bartram J., Boudjogrha M., Bystry V., Fazio G., Fronkova E., Giraud M., Grioni A., Hancock J., Herrmann D., Jimenez C., Krejci A., Moppett J., Reigl T., Salson M., Scheijen B., Schwarz M., Songia S., Svaton M., van Dongen J. J. M., Villarese P., Wakeman S., Wright G., Cazzaniga G., Davi F., Garcia-Sanz R., Gonzalez D., Groenen P. J. T. A., Hummel M., Macintyre E. A., Stamatopoulos K., Pott C., Trka J., Darzentas N., Langerak A. W., Bruggemann, M, Kotrova, M, Knecht, H, Bartram, J, Boudjogrha, M, Bystry, V, Fazio, G, Fronkova, E, Giraud, M, Grioni, A, Hancock, J, Herrmann, D, Jimenez, C, Krejci, A, Moppett, J, Reigl, T, Salson, M, Scheijen, B, Schwarz, M, Songia, S, Svaton, M, van Dongen, J, Villarese, P, Wakeman, S, Wright, G, Cazzaniga, G, Davi, F, Garcia-Sanz, R, Gonzalez, D, Groenen, P, Hummel, M, Macintyre, E, Stamatopoulos, K, Pott, C, Trka, J, Darzentas, N, Langerak, A, Bruggemann M., Kotrova M., Knecht H., Bartram J., Boudjogrha M., Bystry V., Fazio G., Fronkova E., Giraud M., Grioni A., Hancock J., Herrmann D., Jimenez C., Krejci A., Moppett J., Reigl T., Salson M., Scheijen B., Schwarz M., Songia S., Svaton M., van Dongen J. J. M., Villarese P., Wakeman S., Wright G., Cazzaniga G., Davi F., Garcia-Sanz R., Gonzalez D., Groenen P. J. T. A., Hummel M., Macintyre E. A., Stamatopoulos K., Pott C., Trka J., Darzentas N., and Langerak A. W.
- Abstract
Amplicon-based next-generation sequencing (NGS) of immunoglobulin (IG) and T-cell receptor (TR) gene rearrangements for clonality assessment, marker identification and quantification of minimal residual disease (MRD) in lymphoid neoplasms has been the focus of intense research, development and application. However, standardization and validation in a scientifically controlled multicentre setting is still lacking. Therefore, IG/TR assay development and design, including bioinformatics, was performed within the EuroClonality-NGS working group and validated for MRD marker identification in acute lymphoblastic leukaemia (ALL). Five EuroMRD ALL reference laboratories performed IG/TR NGS in 50 diagnostic ALL samples, and compared results with those generated through routine IG/TR Sanger sequencing. A central polytarget quality control (cPT-QC) was used to monitor primer performance, and a central in-tube quality control (cIT-QC) was spiked into each sample as a library-specific quality control and calibrator. NGS identified 259 (average 5.2/sample, range 0–14) clonal sequences vs. Sanger-sequencing 248 (average 5.0/sample, range 0–14). NGS primers covered possible IG/TR rearrangement types more completely compared with local multiplex PCR sets and enabled sequencing of bi-allelic rearrangements and weak PCR products. The cPT-QC showed high reproducibility across all laboratories. These validated and reproducible quality-controlled EuroClonality-NGS assays can be used for standardized NGS-based identification of IG/TR markers in lymphoid malignancies.
- Published
- 2019
6. Erratum: GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses
- Author
-
Sellner, L, Brüggemann, M, Schlitt, M, Knecht, H, Herrmann, D, Reigl, T, Krejci, A, Bystry, V, Darzentas, N, Rieger, M, Dietrich, S, Luft, T, Ho, A D, Kneba, M, and Dreger, P
- Published
- 2017
- Full Text
- View/download PDF
7. High Resolution Igh Repertoire Analysis Reveals the Human Fetal Liver As the Origin of Life-Long, Innate B Lymphopoiesis
- Author
-
Roy, A, Bystry, V, Bohn, G, Goudevenou, K, Reigl, T, Papaioannou, M, Krejci, A, O'Byrne, S, Chaidos, A, Grioni, A, Darzentas, N, Roberts, I, and Karadimitris, A
- Published
- 2019
8. Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS
- Author
-
Knecht, H., Reigl, T., Kotrova, M, Appelt, F., Stewart, P., Bystry, V., Krejčí, A. (Alena), Grioni, A., Pal, K. (Karin) van der, Stranska, K., Plevova, K. (K.), Rijntjes, J., Songia, S., Svaton, M., Fronkova, E., Bartram, J., Scheijen, B. (Blanca), Herrmann, D., Garcia-Sanz, R. (Ramon), Hancock, J., Moppett, J. (John), van Dongen, JJM, Cazzaniga, G. (Gianni), Davi, F. (Frédéric), Groenen, P., Hummel, M. (Michael), Macintyre, E.A. (Elizabeth), Stamatopoulos, K. (Kostas), Trka, J. (Jan), Langerak, A.W. (Anton), Gonzalez, D., Pott, C. (Christiane), Bruggemann, M, Darzentas, N. (Nikos), Knecht, H., Reigl, T., Kotrova, M, Appelt, F., Stewart, P., Bystry, V., Krejčí, A. (Alena), Grioni, A., Pal, K. (Karin) van der, Stranska, K., Plevova, K. (K.), Rijntjes, J., Songia, S., Svaton, M., Fronkova, E., Bartram, J., Scheijen, B. (Blanca), Herrmann, D., Garcia-Sanz, R. (Ramon), Hancock, J., Moppett, J. (John), van Dongen, JJM, Cazzaniga, G. (Gianni), Davi, F. (Frédéric), Groenen, P., Hummel, M. (Michael), Macintyre, E.A. (Elizabeth), Stamatopoulos, K. (Kostas), Trka, J. (Jan), Langerak, A.W. (Anton), Gonzalez, D., Pott, C. (Christiane), Bruggemann, M, and Darzentas, N. (Nikos)
- Abstract
Assessment of clonality, marker identification and measurement of minimal residual disease (MRD) of immunoglobulin (IG) and T cell receptor (TR) gene rearrangements in lymphoid neoplasms using next-generation sequencing (NGS) is currently under intensive development for use in clinical diagnostics. So far, however, there is a lack of suitable quality control (QC) options with regard to standardisation and quality metrics to ensure robust clinical application of such approaches. The EuroClonality-NGS Working Group has therefore established two types of QCs to accompany the NGS-based IG/TR assays. First, a central polytarget QC (cPT-QC) is used to monitor the primer performance of each of the EuroClonality multiplex NGS assays; second, a standardised human cell line-based DNA control is spiked into each patient DNA sample to work as a central in-tube QC and calibrator for MRD quantification (cIT-QC). Having integrated those two reference standards in the ARResT/Interrogate bioinformatic platform, EuroClonality-NGS provides a complete protocol for standardised IG/TR gene rearrangement analysis by NGS with high reproducibility, accuracy and precision for valid marker identification and quantification in diagnostics of lymphoid malignancies.
- Published
- 2019
- Full Text
- View/download PDF
9. A simple RNA target capture NGS strategy for fusion genes assessment in the diagnostics of pediatric B-cell acute lymphoblastic leukemia
- Author
-
Grioni, A, Fazio, G, Rigamonti, S, Bystry, V, Daniele, G, Dostalova, Z, Quadri, M, Saitta, C, Silvestri, D, Songia, S, Storlazzi, C, Biondi, A, Darzentas, N, Cazzaniga, G, Grioni, Andrea, Fazio, Grazia, Rigamonti, Silvia, Bystry, Vojtech, Daniele, Giulia, Dostalova, Zuzana, Quadri, Manuel, Saitta, Claudia, Silvestri, Daniela, Songia, Simona, Storlazzi, Clelia T., Biondi, Andrea, Darzentas, Nikos, Cazzaniga, Giovanni, Grioni, A, Fazio, G, Rigamonti, S, Bystry, V, Daniele, G, Dostalova, Z, Quadri, M, Saitta, C, Silvestri, D, Songia, S, Storlazzi, C, Biondi, A, Darzentas, N, Cazzaniga, G, Grioni, Andrea, Fazio, Grazia, Rigamonti, Silvia, Bystry, Vojtech, Daniele, Giulia, Dostalova, Zuzana, Quadri, Manuel, Saitta, Claudia, Silvestri, Daniela, Songia, Simona, Storlazzi, Clelia T., Biondi, Andrea, Darzentas, Nikos, and Cazzaniga, Giovanni
- Abstract
Acute lymphoblastic leukemia (ALL) is the most frequent pediatric cancer. Fusion genes are hallmarks of ALL, and they are used as biomarkers for risk stratification as well as targets for precision medicine. Hence, clinical diagnostics pursues broad and comprehensive strategies for accurate discovery of fusion genes. Currently, the gold standard methodologies for fusion gene detection are fluorescence in situ hybridization and polymerase chain reaction; these, however, lack sensitivity for the identification of new fusion genes and breakpoints. In this study, we implemented a simple operating procedure (OP) for detecting fusion genes. The OP employs RNA CaptureSeq, a versatile and effortless next-generation sequencing assay, and an in-house as well as a purpose-built bioinformatics pipeline for the subsequent data analysis. The OP was evaluated on a cohort of 89 B-cell precursor ALL (BCP-ALL) pediatric samples annotated as negative for fusion genes by the standard techniques. The OP confirmed 51 samples as negative for fusion genes, and, more importantly, it identified known (KMT2A rearrangements) as well as new fusion events (JAK2 rearrangements) in the remaining 38 investigated samples, of which 16 fusion genes had prognostic significance. Herein, we describe the OP and its deployment into routine ALL diagnostics, which will allow substantial improvements in both patient risk stratification and precision medicine.
- Published
- 2019
10. First evidence of a paediatric patient with Cornelia de Lange syndrome with acute lymphoblastic leukaemia
- Author
-
Fazio, G, Massa, V, Grioni, A, Bystry, V, Rigamonti, S, Saitta, C, Galbiati, M, Rizzari, C, Consarino, C, Biondi, A, Selicorni, A, Cazzaniga, G, Fazio, Grazia, Massa, Valentina, GRIONI, ANDREA, Bystry, Vojtech, Rigamonti, Silvia, Saitta, Claudia, Galbiati, Marta, Rizzari, Carmelo, Consarino, Caterina, Biondi, Andrea, Selicorni, Angelo, Cazzaniga, Giovanni, Fazio, G, Massa, V, Grioni, A, Bystry, V, Rigamonti, S, Saitta, C, Galbiati, M, Rizzari, C, Consarino, C, Biondi, A, Selicorni, A, Cazzaniga, G, Fazio, Grazia, Massa, Valentina, GRIONI, ANDREA, Bystry, Vojtech, Rigamonti, Silvia, Saitta, Claudia, Galbiati, Marta, Rizzari, Carmelo, Consarino, Caterina, Biondi, Andrea, Selicorni, Angelo, and Cazzaniga, Giovanni
- Abstract
Cornelia de Lange syndrome (CdLS) is a rare autosomal-dominant genetic disorder characterised by prenatal and postnatal growth and mental retardation, facial dysmorphism and upper limb abnormalities. Germline mutations of cohesin complex genes SMC1A, SMC3, RAD21 or their regulators NIPBL and HDAC8 have been identified in CdLS as well as somatic mutations in myeloid disorders. We describe the first case of a paediatric patient with CdLS with B-cell precursor Acute Lymphoblastic Leukaemia (ALL). The patient did not show any unusual cytogenetic abnormality, and he was enrolled into the high risk arm of AIEOP-BFM ALL2009 protocol because of slow early response, but 3 years after discontinuation, he experienced an ALL relapse. We identified a heterozygous mutation in exon 46 of NIPBL, causing frameshift and a premature stop codon (RNA-Targeted Next generation Sequencing Analysis). The analysis of the family indicated a de novo origin of this previously not reported deleterious variant. As for somatic cohesin mutations in acute myeloid leukaemia, also this ALL case was not affected by aneuploidy, thus suggesting a major impact of the non-canonical role of NIPBL in gene regulation. A potential biological role of NIPBL in leukaemia has still to be dissected.
- Published
- 2019
11. MULTI-CENTER VALIDATION OF STANDARDIZED NGS ASSAYS FOR REARRANGED IG / TR MARKER DETECTION IN ACUTE LYMPHOBLASTIC LEUKEMIA - A REPORT OF THE EUROCLONALITY-NGS CONSORTIUM
- Author
-
Bruggemann, M., Knecht, H., Kotrova, M., Bartram, J., Bystry, V., Darzentas, N., Davi, F., Fazio, G., Fronkova, E., Garcia-Sanz, R., Giraud, M., Grioni, A., Groenen, P.J., Hancock, J., Herrmann, D., Hummel, M., Jimenez, C., Krejci, A., Pott, C., Riegl, T., Salson, M., Schwarz, M., Songia, S., Svenkrtova, A., Villarese, P., Cazzaniga, G., Dongen, J.J. van, Macintyre, E.A., Mopett, J., Trka, J., and Langerak, A.W.
- Published
- 2017
12. High resolution IgH repertoire analysis reveals fetal liver as the likely origin of life-long, innate B lymphopoiesis in humans
- Author
-
Roy, A, Bystry, V, Bohn, G, Goudevenou, K, Reigl, T, Papaioannou, M, Krejci, A, O'Byrne, S, Chaidos, A, Grioni, A, Darzentas, N, Roberts, IAG, and Karadimitris, A
- Subjects
B-Lymphocytes ,Lymphopoiesis ,Immunology ,High-Throughput Nucleotide Sequencing ,Receptors, Antigen, B-Cell ,Sequence Analysis, DNA ,Leukemia, Lymphocytic, Chronic, B-Cell ,Article ,Fetal ,Fetus ,Immunoglobulin M ,Liver ,Bone Marrow ,1107 Immunology ,IgH repertoire ,Humans ,Immunoglobulin Heavy Chains ,Human - Abstract
The ontogeny of the natural, public IgM repertoire remains incompletely explored. Here, high-resolution immunogenetic analysis of B cells from (unrelated) fetal, child, and adult samples, shows that although fetal liver (FL) and bone marrow (FBM) IgM repertoires are equally diversified, FL is the main source of IgM natural immunity during the 2nd trimester. Strikingly, 0.25% of all prenatal clonotypes, comprising 18.7% of the expressed repertoire, are shared with the postnatal samples, consistent with persisting fetal IgM + B cells being a source of natural IgM repertoire in adult life. Further, the origins of specific stereotypic IgM + B cell receptors associated with chronic lymphocytic leukemia, can be traced back to fetal B cell lymphopoiesis, suggesting that persisting fetal B cells can be subject to malignant transformation late in life. Overall, these novel data provide unique insights into the ontogeny of physiological and malignant B lymphopoiesis that spans the human lifetime., Graphical abstract Image 1, Highlights • Second trimester human fetal liver and fetal bone marrow B-cells have IgM repertoires that are equally diversified • Human fetal liver B-cells are the main source of innate, natural IgM responses • CLL-associated, stereotypic B cell receptors are detected in fetal IgM repertoire
- Published
- 2017
13. Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status
- Author
-
Kubesova, B, primary, Pavlova, S, additional, Malcikova, J, additional, Kabathova, J, additional, Radova, L, additional, Tom, N, additional, Tichy, B, additional, Plevova, K, additional, Kantorova, B, additional, Fiedorova, K, additional, Slavikova, M, additional, Bystry, V, additional, Kissova, J, additional, Gisslinger, B, additional, Gisslinger, H, additional, Penka, M, additional, Mayer, J, additional, Kralovics, R, additional, Pospisilova, S, additional, and Doubek, M, additional
- Published
- 2017
- Full Text
- View/download PDF
14. ARResT/Interrogate: an interactive immunoprofiler for IG/TR NGS data
- Author
-
Bystry, V., Reigl, T., Krejci, A., Demko, M., Hanakova, B., Grioni, A., Knecht, H., Schlitt, M., Dreger, P., Sellner, L., Herrmann, D., Pingeon, M., Boudjoghra, M., Rijntjes, J., Pott, C., Langerak, A.W., Groenen, P.J.T.A., Davi, F., Bruggemann, M., Darzentas, N., Bystry, V., Reigl, T., Krejci, A., Demko, M., Hanakova, B., Grioni, A., Knecht, H., Schlitt, M., Dreger, P., Sellner, L., Herrmann, D., Pingeon, M., Boudjoghra, M., Rijntjes, J., Pott, C., Langerak, A.W., Groenen, P.J.T.A., Davi, F., Bruggemann, M., and Darzentas, N.
- Abstract
Item does not contain fulltext
- Published
- 2017
15. GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses
- Author
-
Sellner, L, primary, Brüggemann, M, additional, Schlitt, M, additional, Knecht, H, additional, Herrmann, D, additional, Reigl, T, additional, Krejci, A, additional, Bystry, V, additional, Darzentas, N, additional, Rieger, M, additional, Dietrich, S, additional, Luft, T, additional, Ho, A D, additional, Kneba, M, additional, and Dreger, P, additional
- Published
- 2016
- Full Text
- View/download PDF
16. HIGHER-ORDER IMMUNOGLOBULIN SEQUENCE RELATIONS FOR MAJOR SUBSETS OF CHRONIC LYMPHOCYTIC LEUKEMIA : UNIQUENESS VERSUS EQUIVALENCE
- Author
-
Agathangelidis, A., Bystry, V., Hadzidimitriou, A., Sutton, L. A., Minga, E., Kienle, D., Davis, Z., Yan, X. J., Shanafelt, T., Boudjogra, M., Plevova, K., Gounari, M., Xochelli, A., Navarro, A., Chatzouli, M., Pedersen, L. B., Baliakas, Panagiotis, Scarfo, L., Rossi, D., Veronese, S., Facco, M., Bikos, V., Karan-Djurasevic, T., Pavlovic, S., Mansouri, Larry, Poiron, C., Chu, C. C., Stalika, E., Giudicelli, V., Panagiotidis, P., Sudarikov, A., Anagnostopoulos, A., Trentin, L., Catherwood, M., Montillo, M., Gaidano, G., Campo, E., Geisler, C. H., Langerak, A. W., Pospisilova, S., Lefranc, M. P., Chiorazzi, N., Oscier, D., Jelinek, D. F., Stilgenbauer, S., Belessi, C., Davi, F., Rosenquist, Richard, Ghia, P., Darzentas, N., Stamatopoulos, Kostas, Agathangelidis, A., Bystry, V., Hadzidimitriou, A., Sutton, L. A., Minga, E., Kienle, D., Davis, Z., Yan, X. J., Shanafelt, T., Boudjogra, M., Plevova, K., Gounari, M., Xochelli, A., Navarro, A., Chatzouli, M., Pedersen, L. B., Baliakas, Panagiotis, Scarfo, L., Rossi, D., Veronese, S., Facco, M., Bikos, V., Karan-Djurasevic, T., Pavlovic, S., Mansouri, Larry, Poiron, C., Chu, C. C., Stalika, E., Giudicelli, V., Panagiotidis, P., Sudarikov, A., Anagnostopoulos, A., Trentin, L., Catherwood, M., Montillo, M., Gaidano, G., Campo, E., Geisler, C. H., Langerak, A. W., Pospisilova, S., Lefranc, M. P., Chiorazzi, N., Oscier, D., Jelinek, D. F., Stilgenbauer, S., Belessi, C., Davi, F., Rosenquist, Richard, Ghia, P., Darzentas, N., and Stamatopoulos, Kostas
- Published
- 2015
17. Higher-order immunoglobulin sequence relations for major subsets of chronic lymphocytic leukemia: uniqueness versus equivalence
- Author
-
Agathangelidis, Andreas, Bystry, V., Hadzidimitriou, A., Sutton, L. A., Minga, Eva, Kienle, D., Davis, Z., Yan, X. J., Shanafelt, T., Boudjogra, M., Plevova, K., Gounari, M., Xochelli, A., Navarro, A., Chatzouli, M., Pedersen, L. B., Baliakas, Panagiotis, Scarfo, L., Rossi, D., Veronese, S., Facco, M., Bikos, V., Karan-Đurašević, Teodora, Pavlović, S., Mansouri, L., Poiron, C., Chu, C. C., Stalika, E., Giudicelli, V., Panagiotidis, P., Sudarikov, A., Anagnostopoulos, Achilles, Trentin, L., Catherwood, M., Montillo, M., Gaidano, G., Campo, E., Geisler, C. H., Langerak, A. W., Pospisilova, S., Lefranc, M. P., Chiorazzi, N., Oscier, D., Jelinek, D. F., Stilgenbauer, S., Belessi, C., Davi, F., Rosenquist, R., Ghia, P., Darzentas, N., Stamatopoulos, K., Agathangelidis, Andreas, Bystry, V., Hadzidimitriou, A., Sutton, L. A., Minga, Eva, Kienle, D., Davis, Z., Yan, X. J., Shanafelt, T., Boudjogra, M., Plevova, K., Gounari, M., Xochelli, A., Navarro, A., Chatzouli, M., Pedersen, L. B., Baliakas, Panagiotis, Scarfo, L., Rossi, D., Veronese, S., Facco, M., Bikos, V., Karan-Đurašević, Teodora, Pavlović, S., Mansouri, L., Poiron, C., Chu, C. C., Stalika, E., Giudicelli, V., Panagiotidis, P., Sudarikov, A., Anagnostopoulos, Achilles, Trentin, L., Catherwood, M., Montillo, M., Gaidano, G., Campo, E., Geisler, C. H., Langerak, A. W., Pospisilova, S., Lefranc, M. P., Chiorazzi, N., Oscier, D., Jelinek, D. F., Stilgenbauer, S., Belessi, C., Davi, F., Rosenquist, R., Ghia, P., Darzentas, N., and Stamatopoulos, K.
- Published
- 2015
18. Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status
- Author
-
Kubesova, B, Pavlova, S, Malcikova, J, Kabathova, J, Radova, L, Tom, N, Tichy, B, Plevova, K, Kantorova, B, Fiedorova, K, Slavikova, M, Bystry, V, Kissova, J, Gisslinger, B, Gisslinger, H, Penka, M, Mayer, J, Kralovics, R, Pospisilova, S, and Doubek, M
- Abstract
The multistep process of TP53 mutation expansion during myeloproliferative neoplasm (MPN) transformation into acute myeloid leukemia (AML) has been documented retrospectively. It is currently unknown how common TP53 mutations with low variant allele frequency (VAF) are, whether they are linked to hydroxyurea (HU) cytoreduction, and what disease progression risk they carry. Using ultra-deep next-generation sequencing, we examined 254 MPN patients treated with HU, interferon alpha-2a or anagrelide and 85 untreated patients. We found TP53 mutations in 50 cases (0.2–16.3% VAF), regardless of disease subtype, driver gene status and cytoreduction. Both therapy and TP53 mutations were strongly associated with older age. Over-time analysis showed that the mutations may be undetectable at diagnosis and slowly increase during disease course. Although three patients with TP53 mutations progressed to TP53-mutated or TP53-wild-type AML, we did not observe a significant age-independent impact on overall survival during the follow-up. Further, we showed that complete p53 inactivation alone led to neither blast transformation nor HU resistance. Altogether, we revealed patient's age as the strongest factor affecting low-burden TP53 mutation incidence in MPN and found no significant age-independent association between TP53 mutations and hydroxyurea. Mutations may persist at low levels for years without an immediate risk of progression.
- Published
- 2018
- Full Text
- View/download PDF
19. HIGHER-ORDER IMMUNOGLOBULIN SEQUENCE RELATIONS FOR MAJOR SUBSETS OF CHRONIC LYMPHOCYTIC LEUKEMIA: UNIQUENESS VERSUS EQUIVALENCE
- Author
-
Agathangelidis, A., Bystry, V., Hadzidimitriou, A., Sutton, L. A., Minga, E., Kienle, D., Davis, Z., Yan, X. J., Shanafelt, T., Boudjogra, M., Plevova, K., Gounari, M., Xochelli, A., Navarro, A., Chatzouli, M., Pedersen, L. B., Baliakas, P., Scarfo, L., Rossi, D., Veronese, S., Facco, M., Bikos, V., Karan-Djurasevic, T., Pavlovic, S., Mansouri, L., Poiron, C., Chu, C. C., Stalika, E., Giudicelli, V., Panagiotidis, P., Andrey Sudarikov, Anagnostopoulos, A., Trentin, L., Catherwood, M., Montillo, M., Gaidano, G., Campo, E., Geisler, C. H., Langerak, A. W., Pospisilova, S., Lefranc, M. P., Chiorazzi, N., Oscier, D., Jelinek, D. F., Stilgenbauer, S., Belessi, C., Davi, F., Rosenquist, R., Ghia, P., Darzentas, N., and Stamatopoulos, K.
20. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study
- Author
-
Brüggemann, Monika, Kotrova, Michaela, Knecht, Henrik, Bartram, Jack, Boudjogrha, Myriam, Bystry, Vojtech, Fazio, Grazia, Froňková, Eva, Giraud, Mathieu, Grioni, Andrea, Hancock, Jeremy, Herrmann, Dietrich, Jimenez, Cristina, Krejci, Adam, Moppett, John, Reigl, Tomas, Salson, Mikaël, Scheijen, Blanca, Schwarz, Martin, Songia, Simona, Svaton, Michael, van Dongen, Jacques, Villarese, Patrick, Wakeman, Stephanie, Wright, Gary, Cazzaniga, Giovanni, Davi, Frédéric, García-Sanz, Ramón, Davi, David, Groenen, Patricia, Hummel, Michael, Macintyre, Elizabeth, Stamatopoulos, Kostas, Pott, Christiane, Trka, Jan, Darzentas, Nikos, Langerak, Anton, Gonzalez, David, Bruggemann, M, Kotrova, M, Knecht, H, Bartram, J, Boudjogrha, M, Bystry, V, Fazio, G, Fronkova, E, Giraud, M, Grioni, A, Hancock, J, Herrmann, D, Jimenez, C, Krejci, A, Moppett, J, Reigl, T, Salson, M, Scheijen, B, Schwarz, M, Songia, S, Svaton, M, van Dongen, J, Villarese, P, Wakeman, S, Wright, G, Cazzaniga, G, Davi, F, Garcia-Sanz, R, Gonzalez, D, Groenen, P, Hummel, M, Macintyre, E, Stamatopoulos, K, Pott, C, Trka, J, Darzentas, N, Langerak, A, Immunology, University Medical Center of Schleswig–Holstein = Universitätsklinikum Schleswig-Holstein (UKSH), Kiel University, Childhood Leukaemia Investigation Prague (CLIP), University Hospital Motol [Prague], Centre de Recherche en Informatique, Signal et Automatique de Lille (CRIStAL) - UMR 9189 (CRIStAL), Centre National de la Recherche Scientifique (CNRS)-Université de Lille-Ecole Centrale de Lille, Facultad de Quimica, Universidad Nacional Autonoma de Mexico, Bioinformatics and Sequence Analysis (BONSAI), Laboratoire d'Informatique Fondamentale de Lille (LIFL), Université de Lille, Sciences et Technologies-Institut National de Recherche en Informatique et en Automatique (Inria)-Université de Lille, Sciences Humaines et Sociales-Centre National de la Recherche Scientifique (CNRS)-Université de Lille, Sciences et Technologies-Institut National de Recherche en Informatique et en Automatique (Inria)-Université de Lille, Sciences Humaines et Sociales-Centre National de la Recherche Scientifique (CNRS)-Inria Lille - Nord Europe, Institut National de Recherche en Informatique et en Automatique (Inria), Liebherr-Werk Nenzing GmbH, Department of Immunology, Laboratory of molecular mechanisms of hematologic disorders and therapeutic implications (ERL 8254 - Equipe Inserm U1163), Imagine - Institut des maladies génétiques (IMAGINE - U1163), Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Bristol Genetics Laboratory, Southmead Hospital, North Bristol NHS Trust, Great Ormond Street Hospital for Children [London] (GOSH), Service d'Hématologie Clinique [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Haematology Department, University Hospital of Salamanca, Hematology Department and University Pierre et Marie Curie, Hopital Pitie-Salpetriere, Paris, France, Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands., Charité - Universitätsmedizin Berlin / Charite - University Medicine Berlin, CHU Necker - Enfants Malades [AP-HP], Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden, University Hospital Schleswig–Holstein, Department of Paediatric Haematology/Oncology, Charles University [Prague], Central European Institute of Technology, Masaryk University, Brno, Czech Republic, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Department of Paediatric Haematology, Department of Hematology, University Hospital Schleswig-Holstein [Kiel, Germany], Service d'Hématologie clinique [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Central European Institute of Technology [Brno] (CEITEC MU), Brno University of Technology [Brno] (BUT), Centro Ricerca Tettamanti, Clinica Pediatrica, Ospedale S. Gerardo-Ospedale S. Gerardo, Centre de Recherche en Informatique, Signal et Automatique de Lille - UMR 9189 (CRIStAL), Centrale Lille-Université de Lille-Centre National de la Recherche Scientifique (CNRS), Bristol Genetics Laboratory (Southmead Hospital), Southmead Hospital, Instituto de Investigación Biomédica de Salamanca (IBSAL), Department of Pediatric Haematology, Bristol Royal Hospital for Children, Department of Pathology [Nijmegen], Radboud University Medical Center [Nijmegen], Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité d'Immunologie et d'Hématologie Pédiatrique (CHU Necker - Enfants Malades [AP-HP]), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Institute of Applied Biosciences, Thessaloniki, Greece., Charles University [Prague] (CU), Centre for Cancer Research and Cell Biology, Queen's University [Belfast] (QUB), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
- Subjects
Genetic Markers ,0301 basic medicine ,Cancer Research ,Neoplasm, Residual ,Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2] ,Receptors, Antigen, T-Cell ,Immunoglobulins ,Computational biology ,Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9] ,Gene Rearrangement, T-Lymphocyte ,Article ,DNA sequencing ,03 medical and health sciences ,symbols.namesake ,All institutes and research themes of the Radboud University Medical Center ,0302 clinical medicine ,Genetics research ,Multiplex polymerase chain reaction ,Humans ,Cancer genetics ,Recombination, Genetic ,Sanger sequencing ,minimal residual disease, next generation sequencing immunoglobulin and T-cell receptor ,Genes, Immunoglobulin ,biology ,Computational Biology ,High-Throughput Nucleotide Sequencing ,Reproducibility of Results ,[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ,Hematology ,Gene rearrangement ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Reference Standards ,Amplicon ,Minimal residual disease ,3. Good health ,Genes, T-Cell Receptor ,030104 developmental biology ,[SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology ,Oncology ,030220 oncology & carcinogenesis ,symbols ,biology.protein ,[INFO.INFO-BI]Computer Science [cs]/Bioinformatics [q-bio.QM] ,Antibody ,Primer (molecular biology) - Abstract
International audience; Amplicon-based next-generation sequencing (NGS) of immunoglobulin (IG) and T-cell receptor (TR) gene rearrangements for clonality assessment, marker identification and quantification of minimal residual disease (MRD) in lymphoid neoplasms has been the focus of intense research, development and application. However, standardization and validation in a scientifically controlled multicentre setting is still lacking. Therefore, IG/TR assay development and design, including bioinformatics, was performed within the EuroClonality-NGS working group and validated for MRD marker identification in acute lymphoblastic leukaemia (ALL). Five EuroMRD ALL reference laboratories performed IG/TR NGS in 50 diagnostic ALL samples, and compared results with those generated through routine IG/TR Sanger sequencing. A central polytarget quality control (cPT-QC) was used to monitor primer performance, and a central in-tube quality control (cIT-QC) was spiked into each sample as a library-specific quality control and calibrator. NGS identified 259 (average 5.2/sample, range 0–14) clonal sequences vs. Sanger-sequencing 248 (average 5.0/sample, range 0–14). NGS primers covered possible IG/TR rearrangement types more completely compared with local multiplex PCR sets and enabled sequencing of bi-allelic rearrangements and weak PCR products. The cPT-QC showed high reproducibility across all laboratories. These validated and reproducible quality-controlled EuroClonality-NGS assays can be used for standardized NGS-based identification of IG/TR markers in lymphoid malignancies.
- Published
- 2019
- Full Text
- View/download PDF
21. STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma
- Author
-
Geeta G. Sharma, Daniel Filip, Marek Mráz, Ivonne-Aidee Montes-Mojarro, Falko Fend, Šárka Pospíšilová, Andrea Janíková, David Belada, Boris Tichy, Nina Prokoph, Katerina Kamaradova, Vojtech Bystry, Luca Mologni, Hugo Larose, Carlo Gambacorti-Passerini, Suzanne D. Turner, Cosimo Lobello, Lenka Radová, Olaf Merkel, Huan-Chang Liang, Lobello, C, Tichy, B, Bystry, V, Radova, L, Filip, D, Mraz, M, Montes-Mojarro, I, Prokoph, N, Larose, H, Liang, H, Sharma, G, Mologni, L, Belada, D, Kamaradova, K, Fend, F, Gambacorti Passerini, C, Merkel, O, Turner, S, Janikova, A, Pospisilova, S, Lobello, Cosimo [0000-0003-1329-2113], Prokoph, Nina [0000-0002-6429-9895], Larose, Hugo [0000-0003-4678-6048], Liang, Huan-Chang [0000-0003-2612-3714], Fend, Falko [0000-0002-5496-293X], Gambacorti-Passerini, Carlo [0000-0001-6058-515X], Turner, Suzanne D. [0000-0002-8439-4507], Pospisilova, Sarka [0000-0001-7136-2680], Apollo - University of Cambridge Repository, and Turner, Suzanne D [0000-0002-8439-4507]
- Subjects
Adult ,Male ,STAT3 Transcription Factor ,Cancer Research ,Letter ,Anaplastic Lymphoma ,Adolescent ,45/22 ,45/23 ,631/67/69 ,CHOP ,medicine.disease_cause ,Tp53 mutation ,ALK P53 ,Young Adult ,hemic and lymphatic diseases ,Genetics research ,Cancer genomics ,medicine ,Humans ,Young adult ,631/208/69 ,STAT3 ,Child ,Anaplastic large-cell lymphoma ,Aged ,Aged, 80 and over ,Mutation ,biology ,business.industry ,692/308/2056 ,45/77 ,Hematology ,Middle Aged ,medicine.disease ,Prognosis ,Lymphoma ,Oncology ,Child, Preschool ,13/51 ,biology.protein ,Cancer research ,Lymphoma, Large-Cell, Anaplastic ,Female ,Tumor Suppressor Protein p53 ,business - Abstract
Funder: European Union’s Horizon 2020 Marie Skłodowska – Curie Innovative Training Networks (ITN - ETN) under grant agreement No.: 675712European Union’s Horizon 2020 Marie Skłodowska – Curie Innovative Training Networks (ITN - ETN) under grant agreement No.: 675712 Czech Science Foundation (GA CR), junior project no. 19-23424Y MEYS CZ project CEITEC 2020 (LQ1601), Funder: MEYS CZ project CEITEC 2020 (LQ1601) NCMG research infrastructure (LM22018132 funded by MEYS CR), Funder: European Union’s Horizon 2020 Marie Skłodowska – Curie Innovative Training Networks (ITN - ETN) under grant agreement No.: 675712., Funder: MH CZ-RVO 65269705
- Published
- 2021
- Full Text
- View/download PDF
22. Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS
- Author
-
Jos Rijntjes, K. Stamatopoulos, C. Pott, Ramón García-Sanz, Karla Plevová, Giovanni Cazzaniga, Elizabeth Macintyre, Nikos Darzentas, Blanca Scheijen, John Moppett, F. Appelt, Jack Bartram, Eva Froňková, Michael Svatoň, Frederic Davi, Michaela Kotrova, Jan Trka, Simona Songia, Kamila Stránská, Andrea Grioni, Henrik Knecht, Monika Brüggemann, David Gonzalez, Dietrich Herrmann, Michael Hummel, Karol Pál, Anthonie Willem Langerak, Tomáš Reigl, Adam Krejci, van Dongen Jjm, Groenen Pjta, J. Hancock, Peter Stewart, Bystry, Immunology, Ministry of Health of the Czech Republic, Associazione Italiana per la Ricerca sul Cancro, Knecht, H, Reigl, T, Kotrova, M, Appelt, F, Stewart, P, Bystry, V, Krejci, A, Grioni, A, Pal, K, Stranska, K, Plevova, K, Rijntjes, J, Songia, S, Svaton, M, Fronkova, E, Bartram, J, Scheijen, B, Herrmann, D, Garcia-Sanz, R, Hancock, J, Moppett, J, van Dongen, J, Cazzaniga, G, Davi, F, Groenen, P, Hummel, M, Macintyre, E, Stamatopoulos, K, Trka, J, Langerak, A, Gonzalez, D, Pott, C, Bruggemann, M, and Darzentas, N
- Subjects
0301 basic medicine ,Genetic Markers ,Quality Control ,Cancer Research ,Neoplasm, Residual ,Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2] ,Receptors, Antigen, T-Cell ,Immunoglobulins ,Human cell line ,Computational biology ,Biology ,Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9] ,DNA sequencing ,Article ,03 medical and health sciences ,0302 clinical medicine ,All institutes and research themes of the Radboud University Medical Center ,SDG 3 - Good Health and Well-being ,Genetic Marker ,Genetics research ,Immunoglobulin ,Humans ,Multiplex ,Cancer genetics ,Gene Rearrangement ,Computational Biology ,High-Throughput Nucleotide Sequencing ,Reproducibility of Results ,Hematology ,Gene rearrangement ,Minimal residual disease ,3. Good health ,Identification (information) ,030104 developmental biology ,Oncology ,Genetic marker ,030220 oncology & carcinogenesis ,Primer (molecular biology) ,Human - Abstract
Assessment of clonality, marker identification and measurement of minimal residual disease (MRD) of immunoglobulin (IG) and T cell receptor (TR) gene rearrangements in lymphoid neoplasms using next-generation sequencing (NGS) is currently under intensive development for use in clinical diagnostics. So far, however, there is a lack of suitable quality control (QC) options with regard to standardisation and quality metrics to ensure robust clinical application of such approaches. The EuroClonality-NGS Working Group has therefore established two types of QCs to accompany the NGS-based IG/TR assays. First, a central polytarget QC (cPT-QC) is used to monitor the primer performance of each of the EuroClonality multiplex NGS assays; second, a standardised human cell line-based DNA control is spiked into each patient DNA sample to work as a central in-tube QC and calibrator for MRD quantification (cIT-QC). Having integrated those two reference standards in the ARResT/Interrogate bioinformatic platform, EuroClonality-NGS provides a complete protocol for standardised IG/TR gene rearrangement analysis by NGS with high reproducibility, accuracy and precision for valid marker identification and quantification in diagnostics of lymphoid malignancies., This work was supported by Ministry of Health of the Czech Republic, grant no. 16-34272A; computational resources were provided by the CESNET LM2015042 and the CERIT Scientific Cloud LM2015085, provided under the programme “Projects of Large Research, Development, and Innovations Infrastructures”. Analyses in Prague (JT, EF and MS) were supported by Ministry of Health, Czech Republic, grant no. 00064203, and by PRIMUS/17/MED/11. Analyses in the Monza (Centro Ricerca Tettamanti, SS, AG and GC) laboratory were supported by the Italian Association for Cancer Research (AIRC) and Comitato Maria Letizia Verga.
- Published
- 2019
- Full Text
- View/download PDF
23. A Simple RNA Target Capture NGS Strategy for Fusion Genes Assessment in the Diagnostics of Pediatric B-cell Acute Lymphoblastic Leukemia
- Author
-
Clelia Tiziana Storlazzi, Zuzana Dostalova, Vojtech Bystry, Giovanni Cazzaniga, Manuel Quadri, Andrea Grioni, Daniela Silvestri, Grazia Fazio, Nikos Darzentas, Andrea Biondi, Claudia Saitta, Simona Songia, Silvia Rigamonti, Giulia Daniele, Grioni, A, Fazio, G, Rigamonti, S, Bystry, V, Daniele, G, Dostalova, Z, Quadri, M, Saitta, C, Silvestri, D, Songia, S, Storlazzi, C, Biondi, A, Darzentas, N, and Cazzaniga, G
- Subjects
Computational biology ,Article ,law.invention ,Fusion gene ,03 medical and health sciences ,0302 clinical medicine ,law ,medicine ,Polymerase chain reaction ,030304 developmental biology ,0303 health sciences ,biology ,medicine.diagnostic_test ,lcsh:RC633-647.5 ,Hematology ,Gold standard (test) ,lcsh:Diseases of the blood and blood-forming organs ,Precision medicine ,medicine.disease ,Pediatric cancer ,3. Good health ,Leukemia ,Leukemia, NGS, BCP-ALL,Fusion genes ,KMT2A ,030220 oncology & carcinogenesis ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,biology.protein ,Fluorescence in situ hybridization - Abstract
Supplemental Digital Content is available in the text, Acute lymphoblastic leukemia (ALL) is the most frequent pediatric cancer. Fusion genes are hallmarks of ALL, and they are used as biomarkers for risk stratification as well as targets for precision medicine. Hence, clinical diagnostics pursues broad and comprehensive strategies for accurate discovery of fusion genes. Currently, the gold standard methodologies for fusion gene detection are fluorescence in situ hybridization and polymerase chain reaction; these, however, lack sensitivity for the identification of new fusion genes and breakpoints. In this study, we implemented a simple operating procedure (OP) for detecting fusion genes. The OP employs RNA CaptureSeq, a versatile and effortless next-generation sequencing assay, and an in-house as well as a purpose-built bioinformatics pipeline for the subsequent data analysis. The OP was evaluated on a cohort of 89 B-cell precursor ALL (BCP-ALL) pediatric samples annotated as negative for fusion genes by the standard techniques. The OP confirmed 51 samples as negative for fusion genes, and, more importantly, it identified known (KMT2A rearrangements) as well as new fusion events (JAK2 rearrangements) in the remaining 38 investigated samples, of which 16 fusion genes had prognostic significance. Herein, we describe the OP and its deployment into routine ALL diagnostics, which will allow substantial improvements in both patient risk stratification and precision medicine.
- Published
- 2019
- Full Text
- View/download PDF
24. First evidence of a paediatric patient with Cornelia de Lange syndrome with acute lymphoblastic leukaemia
- Author
-
Marta Galbiati, Caterina Consarino, Andrea Grioni, Vojtech Bystry, Valentina Massa, Giovanni Cazzaniga, Andrea Biondi, Carmelo Rizzari, Silvia Rigamonti, Grazia Fazio, Claudia Saitta, Angelo Selicorni, Fazio, G, Massa, V, Grioni, A, Bystry, V, Rigamonti, S, Saitta, C, Galbiati, M, Rizzari, C, Consarino, C, Biondi, A, Selicorni, A, and Cazzaniga, G
- Subjects
0301 basic medicine ,Oncology ,Male ,medicine.medical_specialty ,paediatric pathology ,Cornelia de Lange Syndrome ,Heredity ,Cohesin complex ,MED/03 - GENETICA MEDICA ,DNA Mutational Analysis ,Aneuploidy ,Cell Cycle Proteins ,SMC1A ,Pathology and Forensic Medicine ,Frameshift mutation ,03 medical and health sciences ,0302 clinical medicine ,Germline mutation ,molecular oncology ,Recurrence ,Internal medicine ,De Lange Syndrome ,Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ,molecular genetic ,medicine ,Humans ,Genetic Predisposition to Disease ,haemato-oncology ,paediatric haematology ,business.industry ,Genetic disorder ,Proteins ,NIPBL ,General Medicine ,medicine.disease ,Pedigree ,030104 developmental biology ,Phenotype ,030220 oncology & carcinogenesis ,Child, Preschool ,Mutation ,Female ,business - Abstract
Cornelia de Lange syndrome (CdLS) is a rare autosomal-dominant genetic disorder characterised by prenatal and postnatal growth and mental retardation, facial dysmorphism and upper limb abnormalities. Germline mutations of cohesin complex genes SMC1A, SMC3, RAD21 or their regulators NIPBL and HDAC8 have been identified in CdLS as well as somatic mutations in myeloid disorders. We describe the first case of a paediatric patient with CdLS with B-cell precursor Acute Lymphoblastic Leukaemia (ALL). The patient did not show any unusual cytogenetic abnormality, and he was enrolled into the high risk arm of AIEOP-BFM ALL2009 protocol because of slow early response, but 3 years after discontinuation, he experienced an ALL relapse. We identified a heterozygous mutation in exon 46 of NIPBL, causing frameshift and a premature stop codon (RNA-Targeted Next generation Sequencing Analysis). The analysis of the family indicated a de novo origin of this previously not reported deleterious variant. As for somatic cohesin mutations in acute myeloid leukaemia, also this ALL case was not affected by aneuploidy, thus suggesting a major impact of the non-canonical role of NIPBL in gene regulation. A potential biological role of NIPBL in leukaemia has still to be dissected.
- Published
- 2019
25. Real-World Performance of Integrative Clinical Genomics in Pediatric Precision Oncology.
- Author
-
Pokorna P, Palova H, Adamcova S, Jugas R, Al Tukmachi D, Kyr M, Knoflickova D, Kozelkova K, Bystry V, Mejstrikova S, Merta T, Trachtova K, Podlipna E, Mudry P, Pavelka Z, Bajciova V, Tinka P, Jarosova M, Catela Ivkovic T, Madlener S, Pal K, Stepien N, Mayr L, Tichy B, Drabova K, Jezova M, Kozakova S, Vanackova J, Radova L, Steininger K, Haberler C, Gojo J, Sterba J, and Slaby O
- Subjects
- Humans, Child, Female, Male, Child, Preschool, Adolescent, Infant, Gene Expression Profiling, Medical Oncology methods, Cohort Studies, Young Adult, Precision Medicine methods, Neoplasms genetics, Neoplasms therapy, Genomics methods
- Abstract
Despite significant improvement in the survival of pediatric patients with cancer, treatment outcomes for high-risk, relapsed, and refractory cancers remain unsatisfactory. Moreover, prolonged survival is frequently associated with long-term adverse effects due to intensive multimodal treatments. Accelerating the progress of pediatric oncology requires both therapeutic advances and strategies to mitigate the long-term cytotoxic side effects, potentially through targeting specific molecular drivers of pediatric malignancies. In this report, we present the results of integrative genomic and transcriptomic profiling of 230 patients with malignant solid tumors (the "primary cohort") and 18 patients with recurrent or otherwise difficult-to-treat nonmalignant conditions (the "secondary cohort"). The integrative workflow for the primary cohort enabled the identification of clinically significant single nucleotide variants, small insertions/deletions, and fusion genes, which were found in 55% and 28% of patients, respectively. For 38% of patients, molecularly informed treatment recommendations were made. In the secondary cohort, known or potentially driving alteration was detected in 89% of cases, including a suspected novel causal gene for patients with inclusion body infantile digital fibromatosis. Furthermore, 47% of findings also brought therapeutic implications for subsequent management. Across both cohorts, changes or refinements to the original histopathological diagnoses were achieved in 4% of cases. Our study demonstrates the efficacy of integrating advanced genomic and transcriptomic analyses to identify therapeutic targets, refine diagnoses, and optimize treatment strategies for challenging pediatric and young adult malignancies and underscores the need for broad implementation of precision oncology in clinical settings., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
26. Cell-autonomous IL6ST activation suppresses prostate cancer development via STAT3/ARF/p53-driven senescence and confers an immune-active tumor microenvironment.
- Author
-
Sternberg C, Raigel M, Limberger T, Trachtová K, Schlederer M, Lindner D, Kodajova P, Yang J, Ziegler R, Kalla J, Stoiber S, Dey S, Zwolanek D, Neubauer HA, Oberhuber M, Redmer T, Hejret V, Tichy B, Tomberger M, Harbusch NS, Pencik J, Tangermann S, Bystry V, Persson JL, Egger G, Pospisilova S, Eferl R, Wolf P, Sternberg F, Högler S, Lagger S, Rose-John S, and Kenner L
- Subjects
- Male, Animals, Mice, Humans, Cell Line, Tumor, Gene Expression Regulation, Neoplastic, Cyclin-Dependent Kinase Inhibitor p16 metabolism, Cyclin-Dependent Kinase Inhibitor p16 genetics, Disease Models, Animal, STAT3 Transcription Factor metabolism, Prostatic Neoplasms pathology, Prostatic Neoplasms metabolism, Prostatic Neoplasms genetics, Tumor Microenvironment, Tumor Suppressor Protein p53 metabolism, Tumor Suppressor Protein p53 genetics, Cellular Senescence, Signal Transduction
- Abstract
Background: Prostate cancer ranks as the second most frequently diagnosed cancer in men worldwide. Recent research highlights the crucial roles IL6ST-mediated signaling pathways play in the development and progression of various cancers, particularly through hyperactivated STAT3 signaling. However, the molecular programs mediated by IL6ST/STAT3 in prostate cancer are poorly understood., Methods: To investigate the role of IL6ST signaling, we constitutively activated IL6ST signaling in the prostate epithelium of a Pten-deficient prostate cancer mouse model in vivo and examined IL6ST expression in large cohorts of prostate cancer patients. We complemented these data with in-depth transcriptomic and multiplex histopathological analyses., Results: Genetic cell-autonomous activation of the IL6ST receptor in prostate epithelial cells triggers active STAT3 signaling and significantly reduces tumor growth in vivo. Mechanistically, genetic activation of IL6ST signaling mediates senescence via the STAT3/ARF/p53 axis and recruitment of cytotoxic T-cells, ultimately impeding tumor progression. In prostate cancer patients, high IL6ST mRNA expression levels correlate with better recurrence-free survival, increased senescence signals and a transition from an immune-cold to an immune-hot tumor., Conclusions: Our findings demonstrate a context-dependent role of IL6ST/STAT3 in carcinogenesis and a tumor-suppressive function in prostate cancer development by inducing senescence and immune cell attraction. We challenge the prevailing concept of blocking IL6ST/STAT3 signaling as a functional prostate cancer treatment and instead propose cell-autonomous IL6ST activation as a novel therapeutic strategy., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
27. A novel assessment of whole-mount Gleason grading in prostate cancer to identify candidates for radical prostatectomy: a machine learning-based multiomics study.
- Author
-
Ning J, Spielvogel CP, Haberl D, Trachtova K, Stoiber S, Rasul S, Bystry V, Wasinger G, Baltzer P, Gurnhofer E, Timelthaler G, Schlederer M, Papp L, Schachner H, Helbich T, Hartenbach M, Grubmüller B, Shariat SF, Hacker M, Haug A, and Kenner L
- Subjects
- Humans, Male, Aged, Middle Aged, Retrospective Studies, Prospective Studies, Pilot Projects, Positron-Emission Tomography methods, Magnetic Resonance Imaging methods, Genomics methods, Multiomics, Prostatic Neoplasms surgery, Prostatic Neoplasms pathology, Prostatic Neoplasms genetics, Prostatic Neoplasms diagnostic imaging, Machine Learning, Prostatectomy methods, Neoplasm Grading
- Abstract
Purpose : This study aims to assess whole-mount Gleason grading (GG) in prostate cancer (PCa) accurately using a multiomics machine learning (ML) model and to compare its performance with biopsy-proven GG (bxGG) assessment. Materials and Methods : A total of 146 patients with PCa recruited in a pilot study of a prospective clinical trial (NCT02659527) were retrospectively included in the side study, all of whom underwent
68 Ga-PSMA-11 integrated positron emission tomography (PET) / magnetic resonance (MR) before radical prostatectomy (RP) between May 2014 and April 2020. To establish a multiomics ML model, we quantified PET radiomics features, pathway-level genomics features from whole exome sequencing, and pathomics features derived from immunohistochemical staining of 11 biomarkers. Based on the multiomics dataset, five ML models were established and validated using 100-fold Monte Carlo cross-validation. Results : Among five ML models, the random forest (RF) model performed best in terms of the area under the curve (AUC). Compared to bxGG assessment alone, the RF model was superior in terms of AUC (0.87 vs 0.75), specificity (0.72 vs 0.61), positive predictive value (0.79 vs 0.75), and accuracy (0.78 vs 0.77) and showed slightly decreased sensitivity (0.83 vs 0.89) and negative predictive value (0.80 vs 0.81). Among the feature categories, bxGG was identified as the most important feature, followed by pathomics, clinical, radiomics and genomics features. The three important individual features were bxGG, PSA staining and one intensity-related radiomics feature. Conclusion : The findings demonstrate a superior assessment of the developed multiomics-based ML model in whole-mount GG compared to the current clinical baseline of bxGG. This enables personalized patient management by identifying high-risk PCa patients for RP., Competing Interests: Competing Interests: The authors have declared that no competing interest exists., (© The author(s).)- Published
- 2024
- Full Text
- View/download PDF
28. JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression.
- Author
-
Redmer T, Raigel M, Sternberg C, Ziegler R, Probst C, Lindner D, Aufinger A, Limberger T, Trachtova K, Kodajova P, Högler S, Schlederer M, Stoiber S, Oberhuber M, Bolis M, Neubauer HA, Miranda S, Tomberger M, Harbusch NS, Garces de Los Fayos Alonso I, Sternberg F, Moriggl R, Theurillat JP, Tichy B, Bystry V, Persson JL, Mathas S, Aberger F, Strobl B, Pospisilova S, Merkel O, Egger G, Lagger S, and Kenner L
- Subjects
- Male, Animals, Mice, Humans, Senescence-Associated Secretory Phenotype, Proto-Oncogene Proteins c-jun metabolism, Gene Expression Regulation, Neoplastic, Cell Line, Tumor, Gene Expression Profiling, Cellular Senescence genetics, Disease Models, Animal, Prostatic Neoplasms pathology, Prostatic Neoplasms genetics, Prostatic Neoplasms metabolism, PTEN Phosphohydrolase genetics, PTEN Phosphohydrolase metabolism, Disease Progression, Tumor Microenvironment immunology
- Abstract
Background: Prostate cancer develops through malignant transformation of the prostate epithelium in a stepwise, mutation-driven process. Although activator protein-1 transcription factors such as JUN have been implicated as potential oncogenic drivers, the molecular programs contributing to prostate cancer progression are not fully understood., Methods: We analyzed JUN expression in clinical prostate cancer samples across different stages and investigated its functional role in a Pten-deficient mouse model. We performed histopathological examinations, transcriptomic analyses and explored the senescence-associated secretory phenotype in the tumor microenvironment., Results: Elevated JUN levels characterized early-stage prostate cancer and predicted improved survival in human and murine samples. Immune-phenotyping of Pten-deficient prostates revealed high accumulation of tumor-infiltrating leukocytes, particularly innate immune cells, neutrophils and macrophages as well as high levels of STAT3 activation and IL-1β production. Jun depletion in a Pten-deficient background prevented immune cell attraction which was accompanied by significant reduction of active STAT3 and IL-1β and accelerated prostate tumor growth. Comparative transcriptome profiling of prostate epithelial cells revealed a senescence-associated gene signature, upregulation of pro-inflammatory processes involved in immune cell attraction and of chemokines such as IL-1β, TNF-α, CCL3 and CCL8 in Pten-deficient prostates. Strikingly, JUN depletion reversed both the senescence-associated secretory phenotype and senescence-associated immune cell infiltration but had no impact on cell cycle arrest. As a result, JUN depletion in Pten-deficient prostates interfered with the senescence-associated immune clearance and accelerated tumor growth., Conclusions: Our results suggest that JUN acts as tumor-suppressor and decelerates the progression of prostate cancer by transcriptional regulation of senescence- and inflammation-associated genes. This study opens avenues for novel treatment strategies that could impede disease progression and improve patient outcomes., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
29. Radiogenomic markers enable risk stratification and inference of mutational pathway states in head and neck cancer.
- Author
-
Spielvogel CP, Stoiber S, Papp L, Krajnc D, Grahovac M, Gurnhofer E, Trachtova K, Bystry V, Leisser A, Jank B, Schnoell J, Kadletz L, Heiduschka G, Beyer T, Hacker M, Kenner L, and Haug AR
- Subjects
- Humans, Squamous Cell Carcinoma of Head and Neck diagnostic imaging, Squamous Cell Carcinoma of Head and Neck genetics, Retrospective Studies, Genetic Markers, Prognosis, Risk Assessment, Carcinoma, Squamous Cell pathology, Head and Neck Neoplasms diagnostic imaging, Head and Neck Neoplasms genetics
- Abstract
Purpose: Head and neck squamous cell carcinomas (HNSCCs) are a molecularly, histologically, and clinically heterogeneous set of tumors originating from the mucosal epithelium of the oral cavity, pharynx, and larynx. This heterogeneous nature of HNSCC is one of the main contributing factors to the lack of prognostic markers for personalized treatment. The aim of this study was to develop and identify multi-omics markers capable of improved risk stratification in this highly heterogeneous patient population., Methods: In this retrospective study, we approached this issue by establishing radiogenomics markers to identify high-risk individuals in a cohort of 127 HNSCC patients. Hybrid in vivo imaging and whole-exome sequencing were employed to identify quantitative imaging markers as well as genetic markers on pathway-level prognostic in HNSCC. We investigated the deductibility of the prognostic genetic markers using anatomical and metabolic imaging using positron emission tomography combined with computed tomography. Moreover, we used statistical and machine learning modeling to investigate whether a multi-omics approach can be used to derive prognostic markers for HNSCC., Results: Radiogenomic analysis revealed a significant influence of genetic pathway alterations on imaging markers. A highly prognostic radiogenomic marker based on cellular senescence was identified. Furthermore, the radiogenomic biomarkers designed in this study vastly outperformed the prognostic value of markers derived from genetics and imaging alone., Conclusion: Using the identified markers, a clinically meaningful stratification of patients is possible, guiding the identification of high-risk patients and potentially aiding in the development of effective targeted therapies., (© 2022. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
30. Memory B-cell like chronic lymphocytic leukaemia is associated with specific methylation profile of WNT5A promoter and undetectable expression of WNT5A gene.
- Author
-
Poppova L, Pavlova S, Gonzalez B, Kotaskova J, Plevova K, Dumbovic G, Janovska P, Bystry V, Panovska A, Bezdekova L, Maslejova S, Brychtova Y, Doubek M, Krzyzankova M, Borsky M, Mayer J, Bryja V, Alonso S, and Pospisilova S
- Subjects
- Humans, Immunoglobulin Heavy Chains genetics, Immunoglobulin Heavy Chains metabolism, Ligands, DNA Methylation, Promoter Regions, Genetic, Prognosis, Mutation, Wnt-5a Protein genetics, Wnt-5a Protein metabolism, Leukemia, Lymphocytic, Chronic, B-Cell genetics
- Abstract
Genome methylation profiles define naïve-like (n-CLL), memory-like (m-CLL), and intermediate (i-CLL) subsets of chronic lymphocytic leukaemia (CLL). The profiles can be easily determined by the analysis of the five-CpG signature. m-CLL, i-CLL, and n-CLL with the good, intermediate, and poor prognoses, respectively, differ by the somatic hypermutation status of the immunoglobulin heavy chain variable gene (IGHV), a widely used prognostic predictor in CLL. We have previously shown that the expression of WNT5A , encoding a ROR1 ligand, distinguishes patients with the worse outcome within the prognostically favourable IGHV-mutated subgroup. To analyse the mechanisms controlling WNT5A expression, we investigated the methylation status of 54 CpG sites within the WNT5A promoter and its relation to the WNT5A gene expression. In a cohort of 59 CLL patients balanced for combinations of IGHV and WNT5A statuses, we identified three promoter CpG sites whose methylation level correlated with the WNT5A expression within the IGHV-mutated subgroup. Further, we complemented our data with the methylation status of the five-CpG signature. IGHV-mutated/ WNT5A -negative and IGHV-mutated/ WNT5A -positive cases overlapped with m‑CLL and i‑CLL methylation subgroups, respectively, while most IGHV‑unmutated samples were assigned to n-CLL. Median methylation levels of all the three CpG sites in the WNT5A promoter were lowest in i-CLL. Finally, a detailed analysis of m-CLL and i-CLL showed that undetectable WNT5A expression predicts longer treatment-free survival with higher statistical significance than the classification according to the five-CpG signature. To conclude, a favourable m-CLL subgroup is associated with mutated IGHV and undetectable WNT5A expression due to its promoter methylation.
- Published
- 2022
- Full Text
- View/download PDF
31. KMT2C methyltransferase domain regulated INK4A expression suppresses prostate cancer metastasis.
- Author
-
Limberger T, Schlederer M, Trachtová K, Garces de Los Fayos Alonso I, Yang J, Högler S, Sternberg C, Bystry V, Oppelt J, Tichý B, Schmeidl M, Kodajova P, Jäger A, Neubauer HA, Oberhuber M, Schmalzbauer BS, Pospisilova S, Dolznig H, Wadsak W, Culig Z, Turner SD, Egger G, Lagger S, and Kenner L
- Subjects
- Animals, Cyclin-Dependent Kinase Inhibitor p16 genetics, Cyclin-Dependent Kinase Inhibitor p16 metabolism, DNA-Binding Proteins physiology, Humans, Male, Mice, Mutation, Exome Sequencing, Methyltransferases genetics, Prostatic Neoplasms metabolism
- Abstract
Background: Frequent truncation mutations of the histone lysine N-methyltransferase KMT2C have been detected by whole exome sequencing studies in various cancers, including malignancies of the prostate. However, the biological consequences of these alterations in prostate cancer have not yet been elucidated., Methods: To investigate the functional effects of these mutations, we deleted the C-terminal catalytic core motif of Kmt2c specifically in mouse prostate epithelium. We analysed the effect of Kmt2c SET domain deletion in a Pten-deficient PCa mouse model in vivo and of truncation mutations of KMT2C in a large number of prostate cancer patients., Results: We show here for the first time that impaired KMT2C methyltransferase activity drives proliferation and PIN formation and, when combined with loss of the tumour suppressor PTEN, triggers loss of senescence, metastatic dissemination and dramatically reduces life expectancy. In Kmt2c-mutated tumours we show enrichment of proliferative MYC gene signatures and loss of expression of the cell cycle repressor p16
INK4A . In addition, we observe a striking reduction in disease-free survival of patients with KMT2C-mutated prostate cancer., Conclusions: We identified truncating events of KMT2C as drivers of proliferation and PIN formation. Loss of PTEN and KMT2C in prostate cancer results in loss of senescence, metastatic dissemination and reduced life expectancy. Our data demonstrate the prognostic significance of KMT2C mutation status in prostate cancer patients. Inhibition of the MYC signalling axis may be a viable treatment option for patients with KMT2C truncations and therefore poor prognosis., (© 2022. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
32. STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma.
- Author
-
Lobello C, Tichy B, Bystry V, Radova L, Filip D, Mraz M, Montes-Mojarro IA, Prokoph N, Larose H, Liang HC, Sharma GG, Mologni L, Belada D, Kamaradova K, Fend F, Gambacorti-Passerini C, Merkel O, Turner SD, Janikova A, and Pospisilova S
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Humans, Male, Middle Aged, Prognosis, Young Adult, Lymphoma, Large-Cell, Anaplastic genetics, Lymphoma, Large-Cell, Anaplastic pathology, Mutation genetics, STAT3 Transcription Factor genetics, Tumor Suppressor Protein p53 genetics
- Published
- 2021
- Full Text
- View/download PDF
33. First evidence of a paediatric patient with Cornelia de Lange syndrome with acute lymphoblastic leukaemia.
- Author
-
Fazio G, Massa V, Grioni A, Bystry V, Rigamonti S, Saitta C, Galbiati M, Rizzari C, Consarino C, Biondi A, Selicorni A, and Cazzaniga G
- Subjects
- Cell Cycle Proteins, Child, Preschool, DNA Mutational Analysis, De Lange Syndrome diagnosis, Female, Genetic Predisposition to Disease, Heredity, Humans, Male, Pedigree, Phenotype, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma diagnosis, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma therapy, Recurrence, De Lange Syndrome genetics, Mutation, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma genetics, Proteins genetics
- Abstract
Cornelia de Lange syndrome (CdLS) is a rare autosomal-dominant genetic disorder characterised by prenatal and postnatal growth and mental retardation, facial dysmorphism and upper limb abnormalities. Germline mutations of cohesin complex genes SMC1A , SMC3 , RAD21 or their regulators NIPBL and HDAC8 have been identified in CdLS as well as somatic mutations in myeloid disorders. We describe the first case of a paediatric patient with CdLS with B-cell precursor Acute Lymphoblastic Leukaemia (ALL). The patient did not show any unusual cytogenetic abnormality, and he was enrolled into the high risk arm of AIEOP-BFM ALL2009 protocol because of slow early response, but 3 years after discontinuation, he experienced an ALL relapse. We identified a heterozygous mutation in exon 46 of NIPBL , causing frameshift and a premature stop codon (RNA-Targeted Next generation Sequencing Analysis). The analysis of the family indicated a de novo origin of this previously not reported deleterious variant. As for somatic cohesin mutations in acute myeloid leukaemia, also this ALL case was not affected by aneuploidy, thus suggesting a major impact of the non-canonical role of NIPBL in gene regulation. A potential biological role of NIPBL in leukaemia has still to be dissected., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2019
- Full Text
- View/download PDF
34. Bioinformatic pipelines for whole transcriptome sequencing data exploitation in leukemia patients with complex structural variants.
- Author
-
Hynst J, Plevova K, Radova L, Bystry V, Pal K, and Pospisilova S
- Abstract
Background: Extensive genome rearrangements, known as chromothripsis, have been recently identified in several cancer types. Chromothripsis leads to complex structural variants (cSVs) causing aberrant gene expression and the formation of de novo fusion genes, which can trigger cancer development, or worsen its clinical course. The functional impact of cSVs can be studied at the RNA level using whole transcriptome sequencing (total RNA-Seq). It represents a powerful tool for discovering, profiling, and quantifying changes of gene expression in the overall genomic context. However, bioinformatic analysis of transcriptomic data, especially in cases with cSVs, is a complex and challenging task, and the development of proper bioinformatic tools for transcriptome studies is necessary., Methods: We designed a bioinformatic workflow for the analysis of total RNA-Seq data consisting of two separate parts (pipelines): The first pipeline incorporates a statistical solution for differential gene expression analysis in a biologically heterogeneous sample set. We utilized results from transcriptomic arrays which were carried out in parallel to increase the precision of the analysis. The second pipeline is used for the identification of de novo fusion genes. Special attention was given to the filtering of false positives (FPs), which was achieved through consensus fusion calling with several fusion gene callers. We applied the workflow to the data obtained from ten patients with chronic lymphocytic leukemia (CLL) to describe the consequences of their cSVs in detail. The fusion genes identified by our pipeline were correlated with genomic break-points detected by genomic arrays., Results: We set up a novel solution for differential gene expression analysis of individual samples and de novo fusion gene detection from total RNA-Seq data. The results of the differential gene expression analysis were concordant with results obtained by transcriptomic arrays, which demonstrates the analytical capabilities of our method. We also showed that the consensus fusion gene detection approach was able to identify true positives (TPs) efficiently. Detected coordinates of fusion gene junctions were in concordance with genomic breakpoints assessed using genomic arrays., Discussion: Byapplying our methods to real clinical samples, we proved that our approach for total RNA-Seq data analysis generates results consistent with other genomic analytical techniques. The data obtained by our analyses provided clues for the study of the biological consequences of cSVs with far-reaching implications for clinical outcome and management of cancer patients. The bioinformatic workflow is also widely applicable for addressing other research questions in different contexts, for which transcriptomic data are generated., Competing Interests: The authors declare there are no competing interests.
- Published
- 2019
- Full Text
- View/download PDF
35. Activation-induced deaminase and its splice variants associate with trisomy 12 in chronic lymphocytic leukemia.
- Author
-
Zaprazna K, Reblova K, Svobodova V, Radova L, Bystry V, Baloun J, Durechova K, Tom N, Loja T, Buresova M, Stranska K, Oltova A, Doubek M, Atchison ML, Trbusek M, Malcikova J, and Pospisilova S
- Subjects
- Aged, Animals, Chromosomes, Human, Pair 12 enzymology, Chromosomes, Human, Pair 12 genetics, Computer Simulation, Female, Humans, Male, Mice, Mice, Knockout, Middle Aged, Molecular Dynamics Simulation, AICDA (Activation-Induced Cytidine Deaminase), Alternative Splicing, Cytidine Deaminase biosynthesis, Cytidine Deaminase chemistry, Cytidine Deaminase genetics, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Leukemia, Lymphocytic, Chronic, B-Cell enzymology, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Models, Biological, Neoplasm Proteins biosynthesis, Neoplasm Proteins chemistry, Neoplasm Proteins genetics, Trisomy genetics, Trisomy pathology
- Abstract
Activation-induced cytidine deaminase (AID) is a mutator enzyme essential for somatic hypermutation (SHM) and class switch recombination (CSR) during effective adaptive immune responses. Its aberrant expression and activity have been detected in lymphomas, leukemias, and solid tumors. In chronic lymphocytic leukemia (CLL) increased expression of alternatively spliced AID variants has been documented. We used real-time RT-PCR to quantify the expression of AID and its alternatively spliced transcripts (AIDΔE4a, AIDΔE4, AIDivs3, and AIDΔE3E4) in 149 CLL patients and correlated this expression to prognostic markers including recurrent chromosomal aberrations, the presence of complex karyotype, mutation status of the immunoglobulin heavy chain variable gene, and recurrent mutations. We report a previously unappreciated association between higher AID transcript levels and trisomy of chromosome 12. Functional analysis of AID splice variants revealed loss of their activity with respect to SHM, CSR, and induction of double-strand DNA breaks. In silico modeling provided insight into the molecular interactions and structural dynamics of wild-type AID and a shortened AID variant closely resembling AIDΔE4, confirming its loss-of-function phenotype.
- Published
- 2019
- Full Text
- View/download PDF
36. The influence of mutational status and biological characteristics of acute myeloid leukemia on xenotransplantation outcomes in NOD SCID gamma mice.
- Author
-
Culen M, Kosarova Z, Jeziskova I, Folta A, Chovancova J, Loja T, Tom N, Bystry V, Janeckova V, Dvorakova D, Mayer J, and Racil Z
- Subjects
- Adult, Aged, Animals, Heterografts pathology, Humans, Leukemia, Myeloid, Acute blood, Leukocytes, Mice, Mice, Inbred NOD, Mice, SCID, Middle Aged, Nucleophosmin, Transplantation, Heterologous, Young Adult, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute pathology, Mutation
- Abstract
Purpose: This study aimed at analyzing the association of gene mutations and other acute myeloid leukemia (AML) characteristics with engraftment outcomes in immunodeficient mice and to select the engraftment outcomes that best reflect patient survival., Methods: Mutations in 19 genes as well as leukemia- and patient-related characteristics were analyzed for a group of 47 de novo AML samples with respect to three engraftment outcomes: engraftment ability, engraftment intensity (percentage of hCD45
+ cells) and engraftment latency. Leukemia-related characteristics were additionally analyzed in an extended group of 68 samples that included the 47 de novo samples, and additional 21 samples from refractory and relapsed cases. Engraftment outcomes were compared with overall and event-free survival of the patients., Results: For the 47 de novo samples, no single mutation influenced engraftment, whereas the NPM1mut /DNMT3Amut co-mutation was associated with higher engraftment ability. NPM1mut /FLT3-ITDneg had lower engraftment intensity. Among leukemia-related characteristics, a complex karyotype was associated with higher engraftment intensity. Among patient-related characteristics, higher cytogenetic risk was associated with higher engraftment intensity, and failure to achieve clinical remission was associated with shorter engraftment latency. In the extended group of 68 samples, white blood count was associated with higher engraftment ability, and the presence of a complex karyotype was associated with higher engraftment intensity. Association with patient overall survival was seen only for engraftment intensity., Conclusions: The engraftment of AML was influenced by mutation-interactions and other AML characteristics, rather than by single mutated genes, and engraftment intensity best reflected clinical penetrance of AML.- Published
- 2018
- Full Text
- View/download PDF
37. ToTem: a tool for variant calling pipeline optimization.
- Author
-
Tom N, Tom O, Malcikova J, Pavlova S, Kubesova B, Rausch T, Kolarik M, Benes V, Bystry V, and Pospisilova S
- Subjects
- Reproducibility of Results, Research Design, Software, Computational Biology methods, High-Throughput Nucleotide Sequencing methods
- Abstract
Background: High-throughput bioinformatics analyses of next generation sequencing (NGS) data often require challenging pipeline optimization. The key problem is choosing appropriate tools and selecting the best parameters for optimal precision and recall., Results: Here we introduce ToTem, a tool for automated pipeline optimization. ToTem is a stand-alone web application with a comprehensive graphical user interface (GUI). ToTem is written in Java and PHP with an underlying connection to a MySQL database. Its primary role is to automatically generate, execute and benchmark different variant calling pipeline settings. Our tool allows an analysis to be started from any level of the process and with the possibility of plugging almost any tool or code. To prevent an over-fitting of pipeline parameters, ToTem ensures the reproducibility of these by using cross validation techniques that penalize the final precision, recall and F-measure. The results are interpreted as interactive graphs and tables allowing an optimal pipeline to be selected, based on the user's priorities. Using ToTem, we were able to optimize somatic variant calling from ultra-deep targeted gene sequencing (TGS) data and germline variant detection in whole genome sequencing (WGS) data., Conclusions: ToTem is a tool for automated pipeline optimization which is freely available as a web application at https://totem.software .
- Published
- 2018
- Full Text
- View/download PDF
38. GLASS: assisted and standardized assessment of gene variations from Sanger sequence trace data.
- Author
-
Pal K, Bystry V, Reigl T, Demko M, Krejci A, Touloumenidou T, Stalika E, Tichy B, Ghia P, Stamatopoulos K, Pospisilova S, Malcikova J, and Darzentas N
- Subjects
- Alternative Splicing, Humans, Polymorphism, Genetic, Tumor Suppressor Protein p53 genetics, Genotyping Techniques methods, Sequence Analysis, DNA methods, Sequence Analysis, RNA methods, Software
- Abstract
Motivation: Sanger sequencing is still being employed for sequence variant detection by many laboratories, especially in a clinical setting. However, chromatogram interpretation often requires manual inspection and in some cases, considerable expertise., Results: We present GLASS, a web-based Sanger sequence trace viewer, editor, aligner and variant caller, built to assist with the assessment of variations in 'curated' or user-provided genes. Critically, it produces a standardized variant output as recommended by the Human Genome Variation Society., Availability and Implementation: GLASS is freely available at http://bat.infspire.org/genomepd/glass/ with source code at https://github.com/infspiredBAT/GLASS., Contact: nikos.darzentas@gmail.com or malcikova.jitka@fnbrno.cz., Supplementary Information: Supplementary data are available at Bioinformatics online., (© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com)
- Published
- 2017
- Full Text
- View/download PDF
39. High resolution IgH repertoire analysis reveals fetal liver as the likely origin of life-long, innate B lymphopoiesis in humans.
- Author
-
Roy A, Bystry V, Bohn G, Goudevenou K, Reigl T, Papaioannou M, Krejci A, O'Byrne S, Chaidos A, Grioni A, Darzentas N, Roberts IAG, and Karadimitris A
- Subjects
- High-Throughput Nucleotide Sequencing, Humans, Immunoglobulin Heavy Chains immunology, Immunoglobulin M immunology, Leukemia, Lymphocytic, Chronic, B-Cell immunology, Lymphopoiesis immunology, Receptors, Antigen, B-Cell immunology, Sequence Analysis, DNA, B-Lymphocytes immunology, Bone Marrow immunology, Fetus immunology, Immunoglobulin Heavy Chains genetics, Immunoglobulin M genetics, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Liver immunology, Lymphopoiesis genetics, Receptors, Antigen, B-Cell genetics
- Abstract
The ontogeny of the natural, public IgM repertoire remains incompletely explored. Here, high-resolution immunogenetic analysis of B cells from (unrelated) fetal, child, and adult samples, shows that although fetal liver (FL) and bone marrow (FBM) IgM repertoires are equally diversified, FL is the main source of IgM natural immunity during the 2nd trimester. Strikingly, 0.25% of all prenatal clonotypes, comprising 18.7% of the expressed repertoire, are shared with the postnatal samples, consistent with persisting fetal IgM+ B cells being a source of natural IgM repertoire in adult life. Further, the origins of specific stereotypic IgM+ B cell receptors associated with chronic lymphocytic leukemia, can be traced back to fetal B cell lymphopoiesis, suggesting that persisting fetal B cells can be subject to malignant transformation late in life. Overall, these novel data provide unique insights into the ontogeny of physiological and malignant B lymphopoiesis that spans the human lifetime., (Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
40. ARResT/Interrogate: an interactive immunoprofiler for IG/TR NGS data.
- Author
-
Bystry V, Reigl T, Krejci A, Demko M, Hanakova B, Grioni A, Knecht H, Schlitt M, Dreger P, Sellner L, Herrmann D, Pingeon M, Boudjoghra M, Rijntjes J, Pott C, Langerak AW, Groenen PJTA, Davi F, Brüggemann M, and Darzentas N
- Subjects
- Genetic Variation, Humans, Receptors, Antigen, T-Cell genetics, High-Throughput Nucleotide Sequencing methods, Immunogenetics methods, Immunoglobulins genetics, Receptors, Antigen, T-Cell metabolism, Software
- Abstract
Motivation: The study of immunoglobulins and T cell receptors using next-generation sequencing has finally allowed exploring immune repertoires and responses in their immense variability and complexity. Unsurprisingly, their analysis and interpretation is a highly convoluted task., Results: We thus implemented ARResT/Interrogate, a web-based, interactive application. It can organize and filter large amounts of immunogenetic data by numerous criteria, calculate several relevant statistics, and present results in the form of multiple interconnected visualizations., Availability and Implementation: ARResT/Interrogate is implemented primarily in R, and is freely available at http://bat.infspire.org/arrest/interrogate/, Contact: nikos.darzentas@gmail.com, Supplementary Information: Supplementary data are available at Bioinformatics online.
- Published
- 2017
- Full Text
- View/download PDF
41. A role for palindromic structures in the cis-region of maize Sirevirus LTRs in transposable element evolution and host epigenetic response.
- Author
-
Bousios A, Diez CM, Takuno S, Bystry V, Darzentas N, and Gaut BS
- Subjects
- Base Sequence, Conserved Sequence, DNA Methylation, DNA Transposable Elements, Epigenesis, Genetic, Evolution, Molecular, Gene Expression, Gene Expression Regulation, Plant, Genes, Plant, Genes, Viral, Inverted Repeat Sequences, RNA, Small Interfering genetics, Terminal Repeat Sequences, Zea mays metabolism, Plant Viruses genetics, Zea mays genetics
- Abstract
Transposable elements (TEs) proliferate within the genome of their host, which responds by silencing them epigenetically. Much is known about the mechanisms of silencing in plants, particularly the role of siRNAs in guiding DNA methylation. In contrast, little is known about siRNA targeting patterns along the length of TEs, yet this information may provide crucial insights into the dynamics between hosts and TEs. By focusing on 6456 carefully annotated, full-length Sirevirus LTR retrotransposons in maize, we show that their silencing associates with underlying characteristics of the TE sequence and also uncover three features of the host-TE interaction. First, siRNA mapping varies among families and among elements, but particularly along the length of elements. Within the cis-regulatory portion of the LTRs, a complex palindrome-rich region acts as a hotspot of both siRNA matching and sequence evolution. These patterns are consistent across leaf, tassel, and immature ear libraries, but particularly emphasized for floral tissues and 21- to 22-nt siRNAs. Second, this region has the ability to form hairpins, making it a potential template for the production of miRNA-like, hairpin-derived small RNAs. Third, Sireviruses are targeted by siRNAs as a decreasing function of their age, but the oldest elements remain highly targeted, partially by siRNAs that cross-map to the youngest elements. We show that the targeting of older Sireviruses reflects their conserved palindromes. Altogether, we hypothesize that the palindromes aid the silencing of active elements and influence transposition potential, siRNA targeting levels, and ultimately the fate of an element within the genome., (© 2016 Bousios et al.; Published by Cold Spring Harbor Laboratory Press.)
- Published
- 2016
- Full Text
- View/download PDF
42. ARResT/AssignSubsets: a novel application for robust subclassification of chronic lymphocytic leukemia based on B cell receptor IG stereotypy.
- Author
-
Bystry V, Agathangelidis A, Bikos V, Sutton LA, Baliakas P, Hadzidimitriou A, Stamatopoulos K, and Darzentas N
- Subjects
- Humans, Models, Statistical, Leukemia, Lymphocytic, Chronic, B-Cell classification, Receptors, Antigen, B-Cell genetics, Sequence Analysis, DNA methods
- Abstract
Motivation: An ever-increasing body of evidence supports the importance of B cell receptor immunoglobulin (BcR IG) sequence restriction, alias stereotypy, in chronic lymphocytic leukemia (CLL). This phenomenon accounts for ∼30% of studied cases, one in eight of which belong to major subsets, and extends beyond restricted sequence patterns to shared biologic and clinical characteristics and, generally, outcome. Thus, the robust assignment of new cases to major CLL subsets is a critical, and yet unmet, requirement., Results: We introduce a novel application, ARResT/AssignSubsets, which enables the robust assignment of BcR IG sequences from CLL patients to major stereotyped subsets. ARResT/AssignSubsets uniquely combines expert immunogenetic sequence annotation from IMGT/V-QUEST with curation to safeguard quality, statistical modeling of sequence features from more than 7500 CLL patients, and results from multiple perspectives to allow for both objective and subjective assessment. We validated our approach on the learning set, and evaluated its real-world applicability on a new representative dataset comprising 459 sequences from a single institution., Availability and Implementation: ARResT/AssignSubsets is freely available on the web at http://bat.infspire.org/arrest/assignsubsets/, Contact: nikos.darzentas@gmail.com., Supplementary Information: Supplementary data are available at Bioinformatics online., (© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.